An abnormal blood collection diagnosis means a specimen failed pre-analytical quality criteria, not that you have a disease. Laboratories reject or flag roughly 0.3 to 3 percent of venous draws depending on setting, and hemolysis alone accounts for 40 to 70 percent of those rejections worldwide, per a 2018 critical review in Clinical Chemistry and Laboratory Medicine. The label usually describes the tube, not the patient. Rejection criteria are specific: free hemoglobin above 300 mg/dL, a short draw in a citrate tube above 10 percent of target volume, or a clotted EDTA sample. What matters next is whether the deviation could distort a clinical decision.
The mechanism behind an abnormal draw
Every blood collection passes through three phases, and the diagnosis of "abnormal" attaches almost always to the first one. Pre-analytical error covers patient preparation, tourniquet time, needle gauge, tube order, fill volume, and transport temperature. Analytical error belongs to the instrument. Post-analytical error belongs to reporting. Laboratory medicine literature attributes 60 to 70 percent of total diagnostic errors to the pre-analytical phase.
Hemolysis is the dominant mechanism. Red cells shear against a narrow needle bore or rupture under excessive vacuum, releasing hemoglobin, potassium, lactate dehydrogenase, and aspartate aminotransferase into serum. A 21-gauge needle produces far less hemolysis than a 23-gauge butterfly, and a syringe transfer adds another shear step. Potassium rises roughly 0.2 to 1.5 mmol/L per gram of free hemoglobin per liter, which is why a hemolyzed sample can manufacture apparent hyperkalemia in a patient with normal renal function.
Short draws work through a different pathway. Sodium citrate tubes are calibrated for a 9-to-1 blood-to-anticoagulant ratio. Underfill the tube and the citrate concentration rises relative to plasma, chelating calcium and prolonging the partial thromboplastin time artificially. A tube filled to 50 percent of target can extend aPTT by 2 to 4 seconds with no coagulopathy present.
In plain terms: the tube lies about the patient when it is collected badly.
Quantified context: how often, and how much it costs
Rejection rates vary widely by institution and by test menu. Emergency departments and pediatric units sit at the high end, often 1.5 to 3 percent, because of difficult access and small veins. Central inpatient phlebotomy services in mature programs run below 0.5 percent.
| Error type | Share of rejected specimens | Typical measured effect | Common trigger |
|---|---|---|---|
| Hemolysis | 40–70% | K+ up 0.2–1.5 mmol/L; LDH up 2–10× | 23G needle, syringe transfer, vigorous mixing |
| Short draw (citrate) | 5–15% | aPTT prolonged 2–4 s | Underfilled coagulation tube |
| Clotted sample | 3–10% | Fibrin strands, invalid CBC | Incomplete mixing, delayed EDTA inversion |
| Wrong tube or order | 2–8% | Analyte absent or degraded | Draw-order violation |
| Lipemia or icterus interference | 2–6% | Assay-specific bias | Non-fasting draw, severe jaundice |
The downstream cost is not trivial. Repeat collections add an estimated USD 10 to 40 per redraw in consumables and labor, and each one delays a result by 30 to 90 minutes. In a 500-bed hospital drawing 300,000 tubes annually, a 1 percent rejection rate means 3,000 redraws and untold treatment delays.
Time course: from draw to reported result
Timing determines how quickly a deviation is caught and how far it propagates.
| Stage | Typical elapsed time | What can go wrong |
|---|---|---|
| Draw | 0 min | Wrong order, hemolysis, short fill |
| Labeling at bedside | 0–2 min | Mislabeled tube, unlabeled specimen |
| Transport | 15–60 min | Temperature excursion, delay over 2 h |
| Accessioning and screening | 30–120 min | Automated hemolysis index check |
| Analytical run | 60–180 min | Interference detected at result review |
| Result verification | 2–4 h | Delta check flags implausible change |
| Clinician notification | 2–8 h | Repeat requested or result queried |
Modern analyzers measure a hemolysis index automatically, and most laboratories flag results above an index of 50 to 100, corresponding roughly to 50 to 100 mg/dL free hemoglobin. Below that, some assays tolerate the interference and report with a comment. Above the action limit, the result is suppressed and a redraw is requested.
Where it goes wrong by collection site and patient type
The mechanism changes with anatomy. Antecubital veins tolerate a 21-gauge needle and standard vacuum. Hand and forearm veins are smaller, so phlebotomists reach for a 23-gauge butterfly, and hemolysis rates climb with every gauge step above 21. Pediatric and neonatal draws use heel sticks or 23-to-25-gauge butterfly sets, and the smallest patients generate the highest hemolysis indices in most quality databases.
Capillary collections add a separate failure mode. Squeezing the fingertip or heel forces interstitial fluid into the sample, diluting analytes and lysing cells. A heel stick performed without warming can shift glucose and potassium readings appreciably. Arterial punctures carry their own risk profile, with hematoma rates above 5 percent in some series and a separate requirement for immediate air expulsion and ice transport when the specimen is not analyzed within 30 minutes.
Central line draws introduce dilution error. A line used for infusion must be flushed and a discard volume drawn, typically 3 to 10 mL per lumen depending on policy. Skip the discard and you measure the infusate, not the blood.
Misconceptions worth correcting
Hemolysis does not usually come from the patient's disease. A 2020 study of over one million emergency department specimens found that most hemolyzed samples were linked to collection technique rather than intravascular hemolysis, which is rare. The practical consequence: blaming the patient wastes the chance to fix the draw.
A short draw is not automatically rejected by every laboratory. Coagulation tubes with fill below 90 percent of target are commonly rejected, but many chemistry tubes tolerate partial fill because they contain little or no additive. The distinction matters when a nurse asks whether a 2 mL EDTA tube for a complete blood count is acceptable. The answer depends on the analyzer's minimum volume, often 0.5 to 1 mL of whole blood.
Rejection does not mean the result is worthless. A mild hemolysis index between 25 and 50 may be reported with a comment for analytes that are unaffected, such as sodium or creatinine. The clinician should read the comment rather than assume the number is invalid.
A single abnormal draw does not establish a diagnosis of a bleeding disorder, a hemolytic condition, or anything else. It establishes that the specimen is suspect. Confirmation requires a clean repeat collection, ideally by a different phlebotomist using a larger vein.
Red flags that require escalation
Some findings are not routine and should prompt immediate action rather than a quiet redraw.
- Free hemoglobin or hemolysis index far above the assay action limit, with a falling haptoglobin or rising bilirubin, suggesting true intravascular hemolysis rather than a collection artifact.
- A specimen labeled with the wrong patient identifier or a tube drawn from the wrong line, which is a patient safety event requiring incident reporting.
- Potassium above 6.0 mmol/L in a non-hemolyzed sample, or any critical value that arrives with a quality flag.
- Persistent rejection across repeated draws from the same patient, which may signal difficult access, a hypercoagulable state, or an undiagnosed vascular problem.
- A clotted sample in a patient on anticoagulation where the clotting time result governs dosing.
Each of these crosses from quality control into clinical risk and warrants direct communication with the ordering clinician.
What to actually do when a result is flagged
The first action is to read the comment attached to the result, because many flags specify the analyte affected and the magnitude. The second is to decide whether the deviation can alter the clinical decision. A potassium of 5.9 mmol/L in a hemolyzed sample demands a redraw before any treatment. A mildly elevated LDH in the same sample may be repeatable at leisure.
When a redraw is ordered, specify a larger vein, a 21-gauge needle, and a fresh tube of the correct type. Avoid drawing above an infusion site and observe the discard volume. For coagulation studies, fill the citrate tube to the etched line and invert gently five times. For EDTA tubes, invert eight to ten times. Transport at the correct temperature and within the stability window for the analyte.
Ask the laboratory for the hemolysis index if it is not printed. A number between 25 and 100 tells you how much interference to expect. If the index exceeds 100, most chemistry results are unreliable and the sample should be repeated. If a repeat draw is technically difficult, ask whether an alternative specimen type, such as a plasma tube or a point-of-care device, can substitute.
Limits of the evidence and remaining uncertainty
Not every rejection criterion rests on strong evidence. The 10 percent short-draw rule for citrate tubes derives from controlled in vitro studies, but the exact threshold at which aPTT becomes clinically misleading varies with the reagent and the patient's baseline coagulopathy. Some laboratories reject at 90 percent fill, others at 80 percent, and no consensus trial has settled the question.
Hemolysis interference thresholds are similarly assay-specific. A manufacturer may claim tolerance to a hemolysis index of 300 for one analyte and 50 for another, and those figures come from spiking studies that do not perfectly reproduce in vivo conditions. The hemolysis index itself is an approximation, calibrated against a standard and not against the patient's actual free hemoglobin.
The strongest remaining uncertainty concerns whether automated screening actually improves outcomes. Rejection reduces false results, but it also delays care and adds cost. Studies comparing strict and permissive rejection policies show differences in turnaround time and redraw rates, but few link those differences to measurable changes in patient outcomes.
The practical stance is to treat an abnormal blood collection diagnosis as a data quality signal, act on it proportionally to the clinical stakes, and never let a suspect specimen drive an irreversible treatment decision. The diagnosis belongs to the tube until a clean specimen says otherwise.